Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavax): A multi-center phase III clinical trial in healthy adults
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Joon Young | - |
dc.contributor.author | Jeong, Hye Won | - |
dc.contributor.author | Yun, Jong Woo | - |
dc.contributor.author | Lee, Jacob | - |
dc.contributor.author | Woo, Heung Jeong | - |
dc.contributor.author | Bae, Joon-Yong | - |
dc.contributor.author | Park, Man-Seong | - |
dc.contributor.author | Choi, Won Suk | - |
dc.contributor.author | Park, Dae Won | - |
dc.contributor.author | Noh, Ji Yun | - |
dc.contributor.author | Cheong, Hee Jin | - |
dc.contributor.author | Kim, Woo Joo | - |
dc.date.accessioned | 2022-03-14T02:41:48Z | - |
dc.date.available | 2022-03-14T02:41:48Z | - |
dc.date.created | 2021-12-24 | - |
dc.date.issued | 2020-11-25 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/138896 | - |
dc.description.abstract | Background: Hemorrhagic fever with renal syndrome is a serious health problem in Eurasian countries. This study aimed to evaluate the immunogenicity and safety of formalin-inactivated Hantaan virus vaccine (Hantavax (R)) with a 3 + 1 vaccination schedule. Methods: A phase III, multi-center clinical trial was conducted to evaluate the immunogenicity and safety of Hantavax (R) (three primary doses and a booster dose schedule at 0, 1, 2 and 13 months) among healthy adults. Immune responses were assessed using the plaque reduction neutralizing antibody test (PRNT) and immunofluorescent antibody assay (IFA). Systemic and local adverse events were assessed. Results: A total of 320 healthy subjects aged >= 19 years were enrolled. Following three primary doses of Hantavax (R), the seroconversion rate was 80.97% and 92.81% by PRNT and IFA, respectively. With booster administration, seropositive rates were 67.47% and 95.68% at one-month post-vaccination according to PRNT and IFA, respectively. Solicited local and systemic adverse events were reported in 30.50-42.81% and 16.67-33.75% during the three primary dose vaccination, while those were reported 36.57% and 21.36% after the booster doses. Both local and systemic adverse events did not increase with repeated vaccinations. Conclusion: Hantavax (R) showed a high seroconversion rate after the three-dose priming, and additional dose administration with 11-month interval induced good booster effects. (C) 2020 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | HEMORRHAGIC-FEVER | - |
dc.subject | PROTECTIVE EFFECTIVENESS | - |
dc.subject | RENAL SYNDROME | - |
dc.subject | EPIDEMIOLOGY | - |
dc.title | Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavax): A multi-center phase III clinical trial in healthy adults | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Joon Young | - |
dc.contributor.affiliatedAuthor | Park, Man-Seong | - |
dc.contributor.affiliatedAuthor | Choi, Won Suk | - |
dc.contributor.affiliatedAuthor | Park, Dae Won | - |
dc.contributor.affiliatedAuthor | Noh, Ji Yun | - |
dc.contributor.affiliatedAuthor | Cheong, Hee Jin | - |
dc.contributor.affiliatedAuthor | Kim, Woo Joo | - |
dc.identifier.doi | 10.1016/j.vaccine.2020.10.035 | - |
dc.identifier.scopusid | 2-s2.0-85094845477 | - |
dc.identifier.wosid | 000594536100019 | - |
dc.identifier.bibliographicCitation | VACCINE, v.38, no.50, pp.8016 - 8023 | - |
dc.relation.isPartOf | VACCINE | - |
dc.citation.title | VACCINE | - |
dc.citation.volume | 38 | - |
dc.citation.number | 50 | - |
dc.citation.startPage | 8016 | - |
dc.citation.endPage | 8023 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | HEMORRHAGIC-FEVER | - |
dc.subject.keywordPlus | PROTECTIVE EFFECTIVENESS | - |
dc.subject.keywordPlus | RENAL SYNDROME | - |
dc.subject.keywordAuthor | Hantaan virus | - |
dc.subject.keywordAuthor | Hantavirus | - |
dc.subject.keywordAuthor | Immunogenicity | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Vaccine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.